xanomeline
xanomeline: 9 clinical trials tracked.
xanomeline evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about xanomeline, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (9)
A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With Schizophrenia
Primary endpoint: KarXTtreatment pattern according to clinicians'decision
A Multimodal PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
Primary endpoint: [18F]DOPA Kicer ([18F]DOPA relative uptake rate)
Effectiveness and Adverse-effect Switch Evaluation
Primary endpoint: Treatment titration and switch regimens as described by the prescribing clinician
Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Primary endpoint: Participant medication preference as assessed by the Preference of Medication (POM) questionnaire
Phase 1, 4-Part, Open-label (Parts 1 to 3) and Double-blind (Part 4) Study to Evaluate the Pharmacokinetics of Novel KarX (BMS-986519) and KarT (BMS-986520) Prototypes Versus the KarXT (BMS-986510) and KarX-EC (BMS-986519) Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants, and to Evaluate Alternative Formulations of KarX (BMS-986519) and KarXT (BMS-986510) Following Single and Multiple Ascending Doses in Healthy Adult Participants
Primary endpoint: Maximum observed concentration (Cmax)
A Phase 3, Multicenter, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
Primary endpoint: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Scores at Week 5 of the Double-Blind Period
An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Primary endpoint: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs)